$ZS

Geller Adam sold $345K of ZS

Geller Adam (Chief Product Officer) sold 2,817 shares of Zscaler, Inc. (ZS) at $122.60 ($0.35M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Geller Adam
Published Jun 23, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ZS
Neutral
high confidence
Mentioned
$ZS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZSNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price, and post-transaction holdings; however, the pre-arranged 10b5-1 plan reduces interpretive weight for near-term fundamentals.

02

Market read

Traders may note the insider sale for sentiment, but it is unlikely to drive a fundamental repricing absent additional company catalysts.

03

What to watch

The filing does not disclose reasons for the sale beyond the plan structure; without concurrent news (earnings, guidance, major deals), the market impact should be treated as sentiment-only.

Relevance 3/10Novelty 3/10Timing: just-filed SEC Form 4 (filed 2026-06-23) for a 2026-06-22 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Zscaler, Inc. (ZS).

Company-level read

Ticker impact

$ZSNeutralHigh confidence
Context

SEC Form 4 shows Zscaler CPO Adam Geller sold 2,817 shares at $122.60 on 2026-06-22 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a scheduled open-market sale under a pre-arranged 10b5-1 plan, with no accompanying company-specific news (guidance, contracts, litigation, or operational updates).

Market effects

Minimal; this is company-specific insider transaction with no sector-wide regulatory or demand signal.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations; traders may ignore it unless paired with other negative catalysts.

Key entities

  • Zscaler, Inc.

    Issuer of the Form 4 insider transaction; subject of the disclosure.

  • Adam Geller

    Chief Product Officer who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ZSMed

Zscaler (ZS) Sets $8B ARR Goal by FY2031 Amid Mixed Analyst View

Zscaler (ZS) aims to reach $8B in annual recurring revenue by FY2031, a 2.4x increase from current revenue. Analysts' views are mixed, with Morgan Stanley lowering its price target to $185 and UBS raising it to $250. The company's P/S ratio is 10.14x, below its historical median of 18.9x, reflecting market skepticism about growth and profitability.

$ZSMed

ZSCALER (ZS) Maintained by JP Morgan -- Price Target Raised to $

JP Morgan maintained an Overweight rating on Zscaler (ZS) and raised its price target from $215 to $245. The company's GF Value™ suggests it is 28.2% undervalued, with a GF Score™ of 76/100. Insider selling totaled $6.4M over the past three months. Zscaler operates in cloud-native cybersecurity, serving large enterprises and government agencies.

$ZSMed

ZS Maintained by Barclays -- Price Target Raised to $225

Barclays maintained an Overweight rating for Zscaler (ZS) and raised its price target to $225 from $220. GuruFocus values ZS at $296.22, suggesting a 29.1% undervaluation at its current price of $210.08. The company has a GF Score of 76/100, indicating strong growth and valuation but low profitability. Insider selling totaled $6.4M in the last 3 months.